Aquestive Therapeutics Completes In-Person Type A Meeting With FDA Regarding Resubmission Of NDA For Anaphylm Sublingual Film For Treatment Of Type 1 Allergic Reactions, Including Anaphylaxis

Aquestive Therapeutics, Inc. has successfully completed an in-person Type A meeting with the FDA, receiving preliminary comments regarding the resubmission of its New Drug Application (NDA) for Anaphylm™ (dibutepinephrine) sublingual film. This product is intended for the treatment of Type 1 allergic reactions, including anaphylaxis.